Independent CRO Adds Ex Vivo Model to its Claims Substantiation Protocols
Mauritius, November 07, 2017: CIDP, Centre International de Développement Pharmaceutique, a Mauritius-based private and independent Contract Research Organisation (CRO), will bring its full suite of services – comprising research activities, in vitro and ex vivo testing, analytical chemistry, formulation, and clinical research – to in-cosmetics North America 2017. CIDP will also present its innovative anti-pollution and blue light study protocols, and reveal a new ex vivo model at the show.
Earlier this year, CIDP unveiled its innovative study protocol for substantiating anti-pollution claims on cosmetic products. Since then, the company has developed an ex vivo model as an addition to its anti-pollution and blue light claim substantiation protocols. This new model allows experiments to be conducted in conditions close to the in vivo model.
The ex vivo model of viable full-thickness skin explants reproduces the same mechanisms that are activated in the different cell layers of the human skin, enabling CIDP researchers to closely monitor the effects of pollution on the skin.
On 11 October at 11:10am, Mrs Véronique NEWTON, Preclinical Laboratory Manager at CIDP, will present the company’s standard protocols for objective substantiation of anti-pollution claims. She will also share more about CIDP’s successful creation of an ex vivo model that mimics in vivoconditions.
“CIDP aims to be the ideal partner to cosmetic manufacturers for their research needs,” commented Mr Jean-Louis ROULE, CEO of CIDP. “Our anti-pollution and blue light protocols had been well-received in Europe, and we’re excited to introduce our ex vivo protocol at in-cosmetics North America this year. The United States is an important market for CIDP, and we’re looking to build on our success in Europe, and strengthen our international strategy by establishing our presence here.”
Corporate Comm India(CCI Newswire)
